Abatacept

This publication has 11 references indexed in Scilit:

• The PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
  Arthritis & Rheumatism, 2005
• Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition
  New England Journal of Medicine, 2005
• Treatment of Rheumatoid Arthritis by Selective Inhibition of T-Cell Activation with Fusion Protein CTLA4Ig
  New England Journal of Medicine, 2003
• Therapeutic strategies for rheumatoid arthritis
  Nature Reviews Drug Discovery, 2003
• Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose‐finding, double‐blind, placebo‐controlled clinical trial evaluating CTLA‐4Ig and LEA29Y eighty‐five days after the first infusion
  Arthritis & Rheumatism, 2002
• Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
  New England Journal of Medicine, 2000
• Costimulatory B7 Molecules in the Pathogenesis of Infectious and Autoimmune Diseases
  New England Journal of Medicine, 1996
• Prevention and amelioration of collagen‐induced arthritis by blockade of the CD28 co‐stimulatory pathway: requirement for both B7‐1 and B7‐2
  European Journal of Immunology, 1996
• Immunosuppression in Vivo by a Soluble Form of the CTLA-4 T Cell Activation Molecule
  Science, 1992
• CTLA-4 is a second receptor for the B cell activation antigen B7.
  The Journal of Experimental Medicine, 1991